Skip to content
Companies

Reservoir Neuroscience

Drugs that repair the blood-brain barrier in aging

Raised to date

$3M

of $8M offered across 1 Form D filing

Still open
$5M
Investors
2
Last filed
Jun 17, 2026

About

Reservoir Neuroscience is a preclinical biotech developing small-molecule therapeutics that repair the blood-brain barrier and reverse brain vascular pathology in aging and neurodegenerative disease. Co-founded in 2019 by UC Berkeley PhD neuroscientists Aaron Friedman and Vlad Senatorov, the company operates in the San Francisco Bay Area. It uses a proprietary human organ-on-chip platform that grows human blood vessels to model vascular aging and screen compounds. Reservoir says it has identified a first-in-kind compound that reverses disease in blood vessels and repairs barrier damage.

Rather than targeting amyloid or tau, Reservoir treats brain vascular dysfunction and blood-brain barrier breakdown as the upstream driver of neurodegeneration, and discovers against it on a human organ-chip model instead of animal models.

Funding

  • EquityFiled Jun 17, 2026Form D
    $3M/ $8M

Product

Blood-brain barrier repair program

Preclinical CNS therapeutics

A preclinical therapeutic candidate discovered on Reservoir's human vascular organ-chip platform that reverses degenerative changes in brain blood vessels and repairs the damaged blood-brain barrier.

  • First-in-kind compound targeting brain vascular disease rather than protein aggregates
  • Reverses vascular pathology and associated neuroinflammation
  • Discovered on a human organ-on-chip vascular aging model

Built for

Aging adults with age-related neurodegeneration and cognitive decline, reached via pharmaceutical partners and prescribers once a candidate advances through the clinic

People on file